Boeing to Upgrade French AWACS and 2 Other Dow Movers to Watch

The Boeing Company (NYSE:BA): Current price $103.34

On Monday, Boeing reported that it has been awarded a contract valued at $354 million, for a major upgrade to four French E-3F Airborne Warning and Control System (AWACS) aircraft. The upgrade will include electrical, mechanical and structural systems as well as mission hardware, and represents the biggest ever for French AWACS. Work on the first plane by subcontractor Air France Industries has already begun and should be completed by next year, while work on the rest of the fleet is set for completion by 2016.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

ba

3M Company (NYSE:MMM): Current price $112.55

3M Critical & Chronic Care Solutions Division announced on Monday the release of two new products: 3M Cavilon Bathing & Cleansing Wipes, and 3M Cavilon 3-in-1 Total Care Cloths. These new offerings are to assist clinicians in meeting the needs for efficacy and efficiency throughout care settings, and join the line of Cavilon solutions employed in incontinence care applications, which is a worry to patients and caregivers alike. Incontinence can cause the development of incontinence-associated dermatitis, which is known as risk factor in the development of pressure ulcers.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

mmm

Johnson & Johnson (NYSE:JNJ): Current price $85.72

The company says that it would pay as much as $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, which acquisition would reinforce J&J’s role in the field subsequent to buying another experimental prostate-cancer treatment four years ago, which has since become a leading brand. On Monday, J&J said that Aragon’s lead product, ARN-509, has the potential to aid both patients whose prostate cancer has not yet spread to other parts of the body, and patients whose cancer has spread. In comparison, J&J’s star Zytiga treatment, obtained through its $1 billion purchase of Cougar Biotechnology in 2009, was okayed in 2011 only for patients in the second category.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

jnj

Investing Insights: Can Green Mountain Coffee Roasters Continue This Bull Run?

More Articles About:   , ,  

More from The Cheat Sheet